- Conditions
- PCOS, Adolescent Obesity, NAFLD
- Interventions
- Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 21 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 192
matching trials from the live ClinicalTrials.gov search.
- Conditions
- GLP - 1, Bowel Preparation for Colonoscopy
- Interventions
- Continue GLP/GIP
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Cleveland, Florida • Weston, Florida
- Conditions
- Diabetes Mellitus
- Interventions
- HM11260C, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Ohio City, Ohio
- Conditions
- Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
- Conditions
- Healthy Participants
- Interventions
- AZD5004
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes
- Interventions
- Gut motility quantification using a capsule after initiating GLP-1RA therapy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Healthy, Hepatic Insufficiency
- Interventions
- LY3502970
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Weight Loss
- Interventions
- VK2735, Placebo
- Biological
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
- Conditions
- Crohn Disease
- Interventions
- Tirzepatide, Mediterranean diet
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Overweight and Obesity
- Interventions
- Apitegromab, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
- Conditions
- Obesity
- Interventions
- Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
- Drug
- Lead sponsor
- BioAge Labs, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more
- Conditions
- Obesity
- Interventions
- BMF-650
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Polycystic Ovary Syndrome, Obesity
- Interventions
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide, Insulin Glargine and Insulin Lispro
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 814 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 39
- States / cities
- Searcy, Arkansas • Huntington Beach, California • Long Beach, California + 34 more
- Conditions
- Obesity or Overweight
- Interventions
- RGT001-075, Placebo Comparator
- Drug
- Lead sponsor
- Regor Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Huntington Park, California + 31 more
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Interventions
- GLP1-RA (semaglutide)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
- Interventions
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Drug · Behavioral
- Lead sponsor
- Texas Tech University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia, Respiratory Aspiration of Gastric Contents
- Interventions
- Ultrasound of gastric contents
- Diagnostic Test
- Lead sponsor
- Wael Saasouh, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan